Form 4: New Enterprise Associates 16, L.P. Acquires Warrants in NeueHealth, Inc.
SEC Form 4 Filing
New Enterprise Associates 16, L.P. reports acquisition of warrants in NeueHealth, Inc. and indirect beneficial ownership by related entities.
Summary
- New Enterprise Associates 16, L.P. filed a Form 4 with the SEC on October 3, 2024, regarding transactions in NeueHealth, Inc. [NEUE].
- The report details the acquisition of 61,865 warrants (right to buy) at a price of $0.01 on October 1, 2024, exercisable from October 2, 2024, and expiring on April 30, 2029.
- These warrants are related to a Warrantholders Agreement dated April 8, 2024, and a Credit Agreement dated August 4, 2023, as amended.
- The report also indicates that New Enterprise Associates 16, L.P. directly holds 185,594 shares of common stock.
- Indirect beneficial ownership is disclaimed by NEA Partners 16, L.P., NEA 16 GP, LLC, and individual managers of NEA 16 GP due to lack of pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports a transaction.
Positives
- The acquisition of warrants by New Enterprise Associates 16, L.P. could be seen as a positive signal, indicating confidence in the future prospects of NeueHealth, Inc.
Risks
- The disclaimers of beneficial ownership by related entities could indicate a complex ownership structure, potentially increasing monitoring complexity for investors.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders, providing transparency to the market.
Comparison to Industry Standards
- Form 4 filings are a common regulatory requirement for publicly traded companies, ensuring transparency regarding insider transactions.
- The structure of the warrant agreement and credit agreement are typical financial instruments used in corporate finance.
Stakeholder Impact
- The acquisition of warrants could have a minor positive impact on shareholder sentiment, reflecting confidence from a significant investor.
Key Dates
| Date | Description |
|---|---|
| 2023-08-04 | Date of the Credit Agreement between the Issuer and the lenders thereto. |
| 2023-10-02 | Date of Incremental Amendment No. 1 to the Credit Agreement. |
| 2024-04-08 | Date of the Warrantholders Agreement and Incremental Amendment No. 2 to the Credit Agreement. |
| 2024-10-01 | Transaction date for the acquisition of warrants. |
| 2024-10-02 | Date the warrants become exercisable. |
| 2024-10-03 | Date of the SEC filing (Form 4). |
| 2029-04-30 | Expiration date of the warrants. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.